Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Heidelberg University
Sponsor

Heidelberg University

Germany Seminarstrasse 2, Altstadt, 69117 Heidelberg, Germany

About the sponsor

Heidelberg University supports clinical research in advanced solid tumours, with a strong focus on non-small-cell lung cancer and adenocarcinoma of the gastroesophageal junction. Its funded studies address treatment selection in stage IV NSCLC with atypical EGFR mutations and perioperative strategies for resectable upper gastrointestinal cancer.

  • Osimertinib and chemotherapy in advanced NSCLC
  • EGFR-mutated lung cancer
  • Gastroesophageal junction adenocarcinoma
  • Perioperative radiochemotherapy

The oncology portfolio also includes treatment planning around surgical outcomes, progression-free survival, and disease control in locally advanced digestive tract malignancies.

About Specializations

Heidelberg University runs clinical trials in conditions such as Non-small cell lung cancer stage IV, Intracranial aneurysm, Chronic myeloid leukaemia (in remission), Philadelphia positive chronic myeloid leukaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Non-small cell lung cancer stage IV

Recruiting

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Intracranial aneurysm

Recruiting

Study on Managing Risk Factors in Patients with Unruptured Brain Aneurysms Using Carbasalate Calcium and Intensive Blood Pressure Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Heidelberg University

Chronic myeloid leukaemia (in remission)

Not recruiting

Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Heidelberg University

Philadelphia positive chronic myeloid leukaemia

Not recruiting

Study on Ponatinib for Achieving Treatment-Free Remission in Patients with Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Heidelberg University

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Oesophageal adenocarcinoma

Not recruiting

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.